Fluticasone Propionate And Salmeterol
Product Images NDC 53002-1568

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 53002-1568). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)
FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)
FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)
FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)
FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)
FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)
FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)
FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

Figure A (Fp Sal Spl Graphic 08)
FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

Figure B (Fp Sal Spl Graphic 09)
FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

Figure C (Fp Sal Spl Graphic 10)
FDA Label Image

Figure D (Fp Sal Spl Graphic 11)

Figure D (Fp Sal Spl Graphic 11)
FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

Figure E (Fp Sal Spl Graphic 12)
FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

Figure F (Fp Sal Spl Graphic 13)
FDA Label Image

Figure G (Fp Sal Spl Graphic 14)

Figure G (Fp Sal Spl Graphic 14)
FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

Figure H (Fp Sal Spl Graphic 15)
FDA Label Image

Label Image (Lbl530021568)

Label Image (Lbl530021568)